Monoclonal antibody · Antagonist of transmembrane serine protease 6 (matriptase-2) (TMPRSS6) · developed by Disc Medicine
DISC-3405 is a humanized monoclonal antibody that binds TMPRSS6 (matriptase-2), a serine protease expressed mainly in hepatocytes that suppresses hepcidin expression. By blocking TMPRSS6, it is intended to restore BMP-SMAD signaling and raise hepcidin levels, lowering iron availability. It is being studied in polycythemia vera.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06985147 | Phase 2 | Polycythemia Vera (PV) | Active not recruiting | IRON |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Polycythemia Vera (PV)
Updated Oct 18, 2026. Something wrong or missing? Report it on the IRON page.
See IRON's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IRON catalysts and pipeline →